function-related pain score (6.5 vs. 6, p=0.10). The mean volume of drained blood wasted in the study group did not differ significantly from the mean total volume of drained blood in the control group (235 vs. 300 ml, p=0. 14) . Similarly, the mean decrease in postoperative haemoglobin concentration did not differ significantly between the respective groups (2.1 vs. 2.1 mmol/l, p=0.97). A significantly greater proportion of patients received allogenic blood transfusion in the study group than in controls (3/12 vs. 2/55, p<0.01). The study group exhibited significantly higher pain scores during training (1.7 vs. 1.4, p=0.03) and lower escape oxycodone consumption (5 vs. 15 mg/kg, p=0.06) on postoperative day 1 (but not other days). The duration of hospitalisation was also longer (5.5 vs. 4 days, p=0.04). Conclusion. In TKR patients with increased risk of bleeding, blood reinfusion combined with femoral nerve block is safe and comparable to standard methods of pain control (local injection of analgesics).
INTRODUCTION
Total knee replacement (TKR) for patients with cardiovascular diseases, conditions with increased risk of bleeding, and previous thromboembolic events is often associated with considerable postoperative blood loss; the mean drainage volume has been reported to be up to 2760 ml. 1, 2 A tourniquet is typically used to minimise the blood loss. Tranexamic acid (TA) is also used intravenously 15 minutes prior to release of the tourniquet, 3, 4 and is reported to reduce the mean blood loss from 1744 to 1301 ml and the use of allogenic blood transfusion from 20% to 10%. 5 Blood reinfusion is increasingly popular especially in patients with increased risk of bleeding, including those in whom TA is contraindicated.
Treatment for postoperative pain is usually based on epidural or peripheral nerve block combined with pain-escape medication (consisting of maximal dosing with paracetamol, non-steroidal anti-inflammatory drugs, and oral or intravenous opioids). Nonetheless, this is associated with adverse effects, such as nausea, sedation, hypotension, reduced lung capacity, increased cardiac load, urinary retention, and partial motor block. All these effects impede rehabilitation and early discharge.
A new modality for pain relief based on intraor peri-articular local injection of analgesics enables reduced use of systemic analgesics and shorter hospital stay. Patients treated with local injection of analgesics had significantly less pain and used less opioids during the first postoperative 24 hours than those treated by continuous femoral nerve block using a catheter. 6 Blood reinfusion combined with local injection of analgesics may risk exceeding toxic serum concentration, especially in cardiac patients, as drain blood contains high concentrations of analgesics. 7 However, it was reported to be safe in 20 typical patients undergoing TKR. 8 Whether the advantage of blood reinfusion outweighs the disadvantage of not using local injection of analgesics in patients at higher risk of bleeding is not known. We compared patients with increased risk of bleeding who received combined blood reinfusion and femoral nerve block in TKR to regular patients treated routinely.
MATERIALS AND METHODS
A consecutive series of 67 patients who underwent unilateral TKR between November 2007 and April 2008 was included. 12 patients aged 53 to 87 (mean, 73; standard deviation, 10) years with increased risk of bleeding owing to cardiac disease or a previous thromboembolic event received continuous femoral nerve block and blood reinfusion, without injection of TA. The remaining 55 patients aged 46 to 90 (mean, 67; SD, 9) years were controls who received standard postoperative treatment (injection of TA, local injection of analgesics, and suction drainage without reinfusion). The study was approved by the local ethics committee, and informed consent was obtained from each subject.
All operations were performed under spinal anaesthesia (at L2-3/L3-4 level with 3 ml hyperbaric bupivacaine, 5 mg/ml) via a medial parapatellar approach. A tourniquet and a single intra-articular suction drain were used. The patella was resurfaced. Cefuroxime (1.5 g) was given intravenously half an hour before surgery. TA (10 mg/kg) was given to the controls before release of the tourniquet and 3 hours later. Deltaparine (5000 IU/day) was started after surgery and given for 5 days. The drain was removed in the morning of the first postoperative day. Sitting and standing were allowed a few hours after surgery. Active flexion/extension exercises and walking training were initiated the next day.
In the study group, patients received a femoral nerve catheter prior to spinal anaesthesia. An insulated needle attached to a peripheral nerve stimulator was inserted next to the femoral nerve at the level of the inguinal ligament (based on well-known landmarks). While advancing the needle, an initial current of 2 mA was gradually reduced to achieve twitches of the quadriceps at 0.4 mA. At this point, a bolus of 20 ml ropivacaine (10 mg/ml) was injected through the needle, and then a 10-gauge catheter was introduced and connected to the infusion pump. Postoperatively, 6 to 12 ml/h ropivacaine (2 mg/ml) was infused for 48 hours. If needed, a bolus of 20 ml could be given once every 8 hours.
The controls received local injections of analgesics with 100 ml ropivacaine (2 mg/ml). The first 40 ml was injected into the posterior part of the capsule and the intercondylar area prior to cementing the prosthesis. The next 40 ml was injected into the anterior part of the capsule, the collateral ligaments, and subcutaneously around the incision before closure of the wound. The 12-gauge drain was positioned laterally in the joint cavity and a 20-gauge (epidural) catheter was introduced separately from the drain into the posterior part of the joint cavity. After closure of the capsule, the remaining 20 ml was injected into the catheter. At 8 p.m. on the day of surgery and on the following day at 7 a.m., a bolus of 20 ml ropivacaine (10 mg/ml) was injected. The catheter was removed immediately after the second bolus. The drain was closed for 1 hour following bolus injections and removed 2 hours after the second bolus.
All patients received oral paracetamol (1 g x4), ketoprofen (200 mg x1) and immediate-release oxycodone 5 mg as required. Ketoprofen was not given to patients with a history of gastric ulcer or dyspepsia, heart, liver or kidney insufficiency, or allergy to non-steroid anti-inflammatory drugs. They received control-release oxycodone (10-20 mg x2) instead. Ondansetron (preferred) or metoclopramide was used for the treatment of nausea and vomiting. All patients received laxatives.
Pain was assessed using a visual analogue scale (VAS). Knee function was assessed using the Knee Society Score (KSS). Radiographic osteoarthritis was assessed according to the Ahlback and the Kellgren and Laurence classification systems and the minimum joint space width. Swelling and other wound characteristics (seeping, blisters, discolouration) were assessed on postoperative day 2.
Before discharge, patient satisfaction and the decrease in blood haemoglobin concentration were assessed. In patients who received allogenic blood transfusion (transfusion threshold: haemoglobin concentration <6 mmol/l), the prevailing haemoglobin concentration was adjusted in order to calculate the blood loss-related haemoglobin decrease. 9 Continuous variables in the 2 groups were compared using the t test or the Wilcoxon-Mann-Whitney U tests as appropriate, whereas discrete variables were compared using the Fisher's exact test. A p value of <0.05 was considered statistically significant.
RESULTS
In the study group, patients were 5 years older and tended to have a lower preoperative KSS function score (35 [range, 0-90] vs. 45 [range, 0-50], p=0.08) and a higher function-related pain score (6.5 [range, [5] [6] [7] vs. 6 [range, [3] [4] [5] [6] [7] , p=0.10). The difference between the 2 groups was not significant in terms of night pain, pain at rest, KSS knee score, and other patient demographics (Table) .
In the study group, the mean volume of re-infused blood collected during the first 6 postoperative hours was 670 (range, 450-950) ml. The mean volume of blood drained in the following 18 hours was 285 (range, 40-500) ml. Thus, the total blood drainage was 955 (range, 700-1300) ml. The mean volume of drained blood wasted in the study group did not differ significantly from the mean total volume of drained blood in the control group ( 
DISCUSSION
Postoperative blood loss is substantial, including bleeding from the wound, haematoma in the periarticular soft tissues, and bleeding into the joint cavity. In patients with a higher risk of bleeding, a suction drain is usually inserted in the joint cavity. Routine use of drain with or without a vacuum is controversial because suction may increase the risk of bleeding into the joint cavity and forming clinically significant subcutaneous haematomas. 2 In TKR the mean total blood loss was reported to be 1744±804 ml. 5 Allogenic blood transfusion is associated with an increased risk of infections. 10, 11 It is thus recommended to bank their own blood for more severe conditions, as this helps minimise the risk of complications associated with allogenic blood transfusion (infection, incompatible haemolytic reactions, graft versus host disease, metabolic disorders, acute lung injury, and immunomodulation). 10 A reduction in allogenic blood transfusion can be achieved through a restrictive transfusion protocol (transfusion threshold: haemoglobin concentration of 7-8 g/dl), correction of preoperative anaemia with iron, vitamin B12, folic acid, and erythropoietin, reduction of blood loss by administration of TA and local haemostasis with fibrin sealants, glues, and activated recombinant factor 8, and autologous blood reinfusion.
Postoperative autologous blood transfusion (postoperative cell saving [PCS]) markedly reduces the need for allogenic blood transfusion (calculated relative risk, 0.5). 1, 12, 13 It has been reported to reduce the allogenic blood transfusion rate from 30.6% to 8.4%, 14 or 33.3% to 16.6% (and by 80% in terms of volume). 1 The use of TA reduces the need for allogenic blood transfusion by 50% in orthopaedic surgery 3 and by 90% in TKR, 4 without increasing the risk of deep vein thrombosis. 3 Total blood loss is reduced by about 38%, and the number of patients needing allogenic blood transfusion (transfusion threshold: haemoglobin concentration of <9 g/dl) is reduced from 38% to 7.5%. 15 In our study, the transfusion threshold was restrictive, and only 3% of patients receiving TA received allogenic blood transfusion. Other methods to reduce blood loss are intra-articular administration of adrenaline, 16 and avoiding suction via the intra-articular drain. 2 In our study, in patients with increased risk of bleeding, blood reinfusion reduced blood loss by up to 1000 ml, such that the mean decrease in postoperative haemoglobin concentration was similar to that in controls. Nonetheless, there may be severe side-effects when blood reinfusion is used in combination with local injection of analgesics. Patients receiving continuous femoral nerve block had less pain relief than those having local injection of analgesics. They used less opoids because their first choice to treat pain was to increase the reinfusion speed, which was associated with delayed pain relief, which may explain why they experienced more pain. Use of more escape opoids by these patients may be due to similar reason.
The longer duration of hospital stay in our study group was likely due to the femoral nerve block and the fact that these patients were older and had more comorbidity and higher preoperative pain scores. Nonetheless, blood reinfusion reduced blood * Data are shown as mean±SD or median (interquartile range) † Grades 0 to 3 denote unsatisfied, less satisfied, satisfied, and very satisfied, respectively loss and the cardiovascular load on patients with increased risk of bleeding. Blood reinfusion combined with femoral nerve block is safe and comparable to standard methods of pain control (local injection of analgesics), and is especially suitable for TKR patients with increased risk of bleeding.
